For investors
An evidence-led approach to health technology.
CHP is being built as a clinically integrated HealthTech investment platform in Abu Dhabi. This page describes the thesis and the disciplines we intend to apply. It is not an offer, a solicitation or an invitation to invest.
The thesis
Four ideas that shape our decisions.
- 01
Evidence-led selection
Clinical review and validation inform whether an opportunity progresses.
- 02
Staged deployment
Capital follows milestones rather than a single upfront commitment.
- 03
Adoption focus
Workflow, procurement and reimbursement examined as part of the thesis.
- 04
Regional relevance
Global sourcing assessed against deployment in the UAE, Saudi Arabia and the wider GCC.
Risk disciplines
How we intend to approach risk.
- Technology risk
- Independent clinical review, pilots and evidence generation.
- Adoption risk
- Clinician engagement, nursing workflow assessment, usability and operational testing.
- Regulatory risk
- Specialist review of the regulatory, reimbursement and market-access pathway.
- Commercial risk
- Assessment of provider demand, payer engagement, distribution and strategic channels.
These disciplines are intended to improve decision-making. They do not eliminate investment, implementation or clinical risk.
Important context
What this page does not say.
CHP is a company in formation. Nothing on this site confirms incorporation, licensing, regulatory permissions, a launched fund, committed capital or a completed portfolio.
We publish no fund size, target return, investment size or performance information. Any discussion of a potential investment relationship would take place privately and would be subject to the applicable legal and regulatory requirements.
Please read our important disclosures.
Private enquiry
Request a conversation.
Share your details and we will review your enquiry. Please keep your message non-confidential.